Publication
EGFR-RAD51 Fusion: A Targetable Partnership Originated from the Tumor Evolution?
Authors not recorded
J Thorac Oncol2018PMID 29472054stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerLung Adenocarcinomacivic_curation1.00
- drugAfatinibcivic_curation1.00
- geneRAD51civic_curation1.00
- variantRAD51 e24::e4civic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 29472054
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| RAD51 e24::e41 | ||||||||
| Afatinib | Lung Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID12369A 62 year-old female never smoker diagnosed of lung adenocarcinoma that was negative for EGFR and ALK alterations (EGFR hotspot tissue NGS) was treated with carboplatin/ pemetrexed/ bevacizumab (x 6 c… (full text at CIViC) PMID 29472054 · Raez et al., 2018 · Open in CIViC | civic |